Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: jad who wrote (1220)	10/26/1997 9:45:00 PM
From: Robert Busse	Read Replies (1) \| Respond to of 1693

Joe, Thanks for the link to the 10-Q. One thing in particular caught my eye near the end of the report. It says: "Net cash used for investment activities of %5,180,000 related to $2,765,000 in capital expenditures for increased production capacity and product cost reduction and $2,415,000 paid for patent licenses and capitalized patent application costs." The part about $2.765 million for "increased production capacity" sound like real foldin' money spent by a company that is pretty confident about increased future demand for its products. The part about "product cost reduction" sounds like the move to Mexico for certain product assembly to help offset the increased costs brought about by the BD settlement. Anyone have any info on this $2.765 million expenditure??? Any other guesses????